Neoadjuvant gemcitabine and nab-paclitaxel for borderline resectable pancreatic cancers: Intention-to-treat analysis compared with upfront surgery.
Yosuke InoueAkio SaiuraAtsushi ObaYoshihiro OnoYoshihiro MiseHiromichi ItoTakashi SasakiMasato OzakaNaoki SasahiraYu TakahashiPublished in: Journal of hepato-biliary-pancreatic sciences (2020)
Intention-to-treat-based analysis indicated considerable benefits of GNP-NAT in BR-PCs for long-term survival, contributing to improved tumor suppression and patient selection.